A next-generation form of chemotherapy from AstraZeneca and Daiichi Sankyo has won Food and Drug Administration authorization for a form of breast cancer, the first U.S. approval for a drug for which the companies have high expectations.
The FDA on Friday announced it had approved the drug, to be marketed as Datroway, for certain advanced breast cancer patients. Datroway, also called datopotamab deruxtecan, or Dato-DXd, was approved in Japan for a form of breast cancer last month, its first regulatory green light.
The U.S. list price for Datroway is roughly $4,900 per 100 milligram vial, and the recommended dose of the drug is 6 milligrams per kilogram of patient weight every three weeks.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in